Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases
Background: The COVID-19 pandemic has brought increased focus on hydroxychloroquine (HCQ), as doctors, the medical community, and policymakers around the world attempt to understand how the risks of HCQ weigh against unknown benefits. We aim to evaluate the effects of HCQ on cardiac conduction, thus...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-04-01
|
| Series: | Kidney Diseases |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/515278 |
| _version_ | 1818672179586269184 |
|---|---|
| author | Yanting Yu Jianteng Xu Anni Xie Sijia Liu Xiaojian Wang Runzhang Zhu Xiaoyan Wang |
| author_facet | Yanting Yu Jianteng Xu Anni Xie Sijia Liu Xiaojian Wang Runzhang Zhu Xiaoyan Wang |
| author_sort | Yanting Yu |
| collection | DOAJ |
| description | Background: The COVID-19 pandemic has brought increased focus on hydroxychloroquine (HCQ), as doctors, the medical community, and policymakers around the world attempt to understand how the risks of HCQ weigh against unknown benefits. We aim to evaluate the effects of HCQ on cardiac conduction, thus contributing to the global understanding of implications of HCQ use. Methods: We reviewed 717 cases of nonmalaria patients treated with HCQ (302) or without HCQ (415) in our hospital from 2008 to 2019, analyzed the cardiac conduction recorded by electrocardiogram (122 vs. 180) including heart rate (HR), PR, and corrected-QT (QTc) intervals, and explored the relationship of cardiac conduction with age, HCQ dosage, HCQ duration, sex, and primary diseases in HCQ users. Results: The all-cause mortality is similar between HCQ and non-HCQ groups (4.0 vs. 4.3%, p = 0.85). Patients aged 45 years or older, not younger ones, have lower HR (80.1 ± 1.7 vs. 85.7 ± 1.8 bpm, p = 0.03) but longer PR (163 ± 3.4 vs. 146.6 ± 4.2 ms, p = 0.003) and QTc (417.8 ± 3.8 vs. 407.7 ± 2.7 ms, p = 0.03) in HCQ than those in non-HCQ. The age in the HCQ group is positively correlated with PR (R = 0.31, p < 0.01) and QTc (R = 0.34, p < 0.01) but not HR. HR, PR, and QTc are not related to HCQ dosage (0.1–0.6 g/day), HCQ duration (0.2–126 months), sex, primary diseases, and repeated exams. Conclusion: Age is the most important risk factor of HCQ on cardiac conduction in nonmalaria patients. Electrocardiogram monitoring is suggested in aged patients due to the effects of HCQ on HR, PR, and QTc. |
| first_indexed | 2024-12-17T07:35:47Z |
| format | Article |
| id | doaj.art-0989847419a94e7a8df09e87cee27e2d |
| institution | Directory Open Access Journal |
| issn | 2296-9381 2296-9357 |
| language | English |
| last_indexed | 2024-12-17T07:35:47Z |
| publishDate | 2021-04-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney Diseases |
| spelling | doaj.art-0989847419a94e7a8df09e87cee27e2d2022-12-21T21:58:19ZengKarger PublishersKidney Diseases2296-93812296-93572021-04-0111010.1159/000515278515278Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria DiseasesYanting Yu0Jianteng Xu1Anni Xie2Sijia Liu3Xiaojian Wang4Runzhang Zhu5Xiaoyan Wang6Department of Nephrology, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Clinical Laboratory, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Nephrology, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Nephrology, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Nephrology, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Nephrology, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Nephrology, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, ChinaBackground: The COVID-19 pandemic has brought increased focus on hydroxychloroquine (HCQ), as doctors, the medical community, and policymakers around the world attempt to understand how the risks of HCQ weigh against unknown benefits. We aim to evaluate the effects of HCQ on cardiac conduction, thus contributing to the global understanding of implications of HCQ use. Methods: We reviewed 717 cases of nonmalaria patients treated with HCQ (302) or without HCQ (415) in our hospital from 2008 to 2019, analyzed the cardiac conduction recorded by electrocardiogram (122 vs. 180) including heart rate (HR), PR, and corrected-QT (QTc) intervals, and explored the relationship of cardiac conduction with age, HCQ dosage, HCQ duration, sex, and primary diseases in HCQ users. Results: The all-cause mortality is similar between HCQ and non-HCQ groups (4.0 vs. 4.3%, p = 0.85). Patients aged 45 years or older, not younger ones, have lower HR (80.1 ± 1.7 vs. 85.7 ± 1.8 bpm, p = 0.03) but longer PR (163 ± 3.4 vs. 146.6 ± 4.2 ms, p = 0.003) and QTc (417.8 ± 3.8 vs. 407.7 ± 2.7 ms, p = 0.03) in HCQ than those in non-HCQ. The age in the HCQ group is positively correlated with PR (R = 0.31, p < 0.01) and QTc (R = 0.34, p < 0.01) but not HR. HR, PR, and QTc are not related to HCQ dosage (0.1–0.6 g/day), HCQ duration (0.2–126 months), sex, primary diseases, and repeated exams. Conclusion: Age is the most important risk factor of HCQ on cardiac conduction in nonmalaria patients. Electrocardiogram monitoring is suggested in aged patients due to the effects of HCQ on HR, PR, and QTc.https://www.karger.com/Article/FullText/515278cardiac conductionelectrocardiogramhydroxychloroquinecoronavirus disease 2019 |
| spellingShingle | Yanting Yu Jianteng Xu Anni Xie Sijia Liu Xiaojian Wang Runzhang Zhu Xiaoyan Wang Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases Kidney Diseases cardiac conduction electrocardiogram hydroxychloroquine coronavirus disease 2019 |
| title | Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases |
| title_full | Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases |
| title_fullStr | Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases |
| title_full_unstemmed | Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases |
| title_short | Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases |
| title_sort | hydroxychloroquine inhibits cardiac conduction in aged patients with nonmalaria diseases |
| topic | cardiac conduction electrocardiogram hydroxychloroquine coronavirus disease 2019 |
| url | https://www.karger.com/Article/FullText/515278 |
| work_keys_str_mv | AT yantingyu hydroxychloroquineinhibitscardiacconductioninagedpatientswithnonmalariadiseases AT jiantengxu hydroxychloroquineinhibitscardiacconductioninagedpatientswithnonmalariadiseases AT annixie hydroxychloroquineinhibitscardiacconductioninagedpatientswithnonmalariadiseases AT sijialiu hydroxychloroquineinhibitscardiacconductioninagedpatientswithnonmalariadiseases AT xiaojianwang hydroxychloroquineinhibitscardiacconductioninagedpatientswithnonmalariadiseases AT runzhangzhu hydroxychloroquineinhibitscardiacconductioninagedpatientswithnonmalariadiseases AT xiaoyanwang hydroxychloroquineinhibitscardiacconductioninagedpatientswithnonmalariadiseases |